Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 75Colorectal Neoplasms 43Rectal Neoplasms 42Stomach Neoplasms 39Triple Negative Breast Neoplasms 30Neoplasm Metastasis 19Esophageal Neoplasms 16Colonic Neoplasms 16Neoplasms 13Pancreatic Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Nasopharyngeal Carcinoma 11Adenocarcinoma 11Biliary Tract Neoplasms 10Adenocarcinoma Of Esophagus 9Cholangiocarcinoma 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Brain Neoplasms 6Anus Neoplasms 6Recurrence 5Neuroendocrine Tumors 5Gastrointestinal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4HER2-positive Breast Cancer 4Colorectal Cancer Metastatic 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Pathologic Complete Response 3

Interventions

trastuzumab deruxtecan 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Cisplatin 2Capecitabine 2pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Capecitabine × 1 year × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡